Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Dose-finding, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of BAY 3283142 on Top of Standard of Care in Reducing Albuminuria in Patients With Chronic Kidney Disease

NCT06522997 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06522997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06522997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Dose-finding, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of BAY 3283142 on Top of Standard of Care in Reducing Albuminuria in Patients With Chronic Kidney Disease
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2024
Completion date
November 20, 2025
Enrollment
1,222 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease